Form 13-F position report

EDGEWISE THERAPEUTICS INC

Reported by DAFNA Capital Management LLC

EWTX CUSIP 28036F105 Manager CIK 0001389933

Reported 290,197 shares, down 16,000 (5.2%) from the prior quarter.

Reported value -6.4%; share count -5.2% vs. the prior quarter.

Reduced
% of reported 13F value 1.25% This manager · Q2 2024
Shares 290,197 Quarter-end amount reported
Reported value $5,226,448 Fair value at quarter end
Consecutive quarters held 10 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 3460000
2022-06-30 5540000
2022-09-30 7686000
2022-12-31 6855576
2023-03-31 4890704
2023-06-30 4025226
2023-09-30 2976070
2023-12-31 4916261
2024-03-31 5585033
2024-06-30 5226448
2024-09-30 6082811
2024-12-31 4996638
2025-03-31 4029080
2025-06-30 3122015
2025-09-30 3466798
2025-12-31 3963849
2026-03-31 3535434
2026-06-30 9215656
2026-09-30 9005851

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for EDGEWISE THERAPEUTICS INC held by DAFNA Capital Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 221,819 -5,000 (-2.2%) 1.92% $9,005,851 2026-11-16
Q2 2026 Added 226,819 +114,583 (102.1%) 1.76% $9,215,656 2026-08-14
Q1 2026 Reduced 112,236 -47,500 (-29.7%) 0.8% $3,535,434 2026-05-15
Q4 2025 Reduced 159,736 -54,000 (-25.3%) 0.92% $3,963,849 2026-02-17
Q3 2025 Reduced 213,736 -24,404 (-10.2%) 0.86% $3,466,798 2025-11-14
Q2 2025 Added 238,140 +55,000 (30.0%) 0.86% $3,122,015 2025-08-14
Q1 2025 Reduced 183,140 -4,000 (-2.1%) 1.14% $4,029,080 2025-05-15
Q4 2024 Reduced 187,140 -40,766 (-17.9%) 1.27% $4,996,638 2025-02-14
Q3 2024 Reduced 227,906 -62,291 (-21.5%) 1.44% $6,082,811 2024-11-14
Q2 2024 Reduced 290,197 -16,000 (-5.2%) 1.25% $5,226,448 2024-08-14
Q1 2024 Reduced 306,197 -143,187 (-31.9%) 1.27% $5,585,033 2024-05-15
Q4 2023 Reduced 449,384 -70,000 (-13.5%) 1.18% $4,916,261 2024-02-14
Q3 2023 Unchanged 519,384 0 (0.0%) 0.93% $2,976,070 2023-11-14
Q2 2023 Reduced 519,384 -213,855 (-29.2%) 1.1% $4,025,226 2023-08-14
Q1 2023 Reduced 733,239 -33,604 (-4.4%) 1.47% $4,890,704 2023-05-15
Q4 2022 Reduced 766,843 -14,269 (-1.8%) 1.93% $6,855,576 2023-02-14
Q3 2022 Added 781,112 +85,153 (12.2%) 2.07% $7,686,000 2022-11-14
Q2 2022 Added 695,959 +339,209 (95.1%) 1.51% $5,540,000 2022-08-15
Q1 2022 New 356,750 +356,750 (0.0%) 0.9% $3,460,000 2022-05-16

Who else reported the position

162 managers reported EDGEWISE THERAPEUTICS INC for Q2 2024.

Managers reporting EDGEWISE THERAPEUTICS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ORBIMED ADVISORS LLC Unchanged 15,021,721 0 5.38% $270,541,195 14 qtrs
RA CAPITAL MANAGEMENT L P Unchanged 8,909,091 0 2.12% $160,452,729 2 qtrs
Novo Holdings A S New 6,344,430 +6,344,430 6.16% $114,263,184 14 qtrs
BlackRock Inc Added 6,015,711 +848,705 < 0.01% $108,342,955 14 qtrs
BAKER BROS ADVISORS LP Unchanged 5,840,059 0 1.34% $105,179,463 14 qtrs
FMR LLC Reduced 4,780,563 -1,585,161 < 0.01% $86,097,933 14 qtrs
VANGUARD GROUP INC Added 4,508,166 +490,733 < 0.01% $81,192,069 14 qtrs
Frazier Life Sciences Management L P Added 3,731,067 +427,500 3.14% $67,196,517 6 qtrs
Cormorant Asset Management LP Unchanged 3,006,534 0 3.13% $54,147,677 14 qtrs
DEERFIELD MANAGEMENT COMPANY L P SERIES C Unchanged 2,874,586 0 0.86% $51,771,294 14 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
290,197
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.